Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and/or Refractory Solid Tumors

NCT06840886 is registered in ClinicalTrials.gov with Pheast Therapeutics as lead sponsor.

NCT NCT06840886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06840886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and/or Refractory Solid Tumors
Lead sponsor
Pheast Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
March 31, 2025
Completion date
April 30, 2031
Enrollment
426 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, breast cancer, carcinosarcoma, ovarian, cholangiocarcinoma, cns tumor, endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma